Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
11/02/16
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
11/17/164Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/17/164Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/02/1610-QQuarterly report which provides a continuing view of a company's financial positionQuarterly Filings Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF Download XBRL Content
11/02/168-KReport of unscheduled material events or corporate eventCurrent Reports Download SEC Filing to Word Download SEC Filing to Excel Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
10/07/164Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
11/29/16Pacira Pharmaceuticals and GeneAlign Announce Partnership to Develop Low-Opioid Pain Management Protocols for Postsurgical Patients at High Risk of Addiction
Collaboration will leverage genetic testing to identify patients predisposed to developing addiction following opioid exposure PARSIPPANY, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced a joint endeavor with GeneAlign, a therapeutic management and solutions company working to revolutionize personalized medicine through a patient-specific opioid risk assessment program that includes behavioral surveys, educational tools and genetic testing. U... 
Printer Friendly Version
11/22/16American College of Surgeons Launches Education Program on Opioids and Surgery: Use, Abuse, and Alternatives
Pacira grant will allow for the development and distribution of resources to educate patients and surgeons on opioid use in surgical care CHICAGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- The American College of Surgeons (ACS) today announced a new multifaceted initiative to improve the knowledge and management of pain in surgical patients with a focus on opioid risk and non-opioid alternatives. With an educational grant from Pacira Pharmaceuticals, Inc. (Pacira), ACS will develop Opioids and Sur... 
Printer Friendly Version
11/11/16Pacira Pharmaceuticals Unveils Virtual Reality Training Simulation to Enhance Administration Technique Education for EXPAREL® in Total Knee Replacement Surgery
3D Mobile Simulation Will Also Debut in Pacira Booth #907 at AAHKS 2016 PARSIPPANY, N.J., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today introduced a revolutionary new virtual reality simulation intended to provide clinicians with an immersive, hands-on training experience to reinforce the recommended technique for administering EXPAREL (bupivacaine liposome injectable suspension) in total knee arthroplasty (TKA) based on the infiltration protocol developed... 
Printer Friendly Version
11/10/16Correction: Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
PARSIPPANY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that senior leadership is scheduled to present an overview of the company at the following investor conferences in November: Jefferies 2016 London Healthcare Conference at 2:00 p.m. GMT (9:00 a.m. ET) in London on Thursday, November 17, 2016. 28th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET in New York on Tuesday, November 29, 2016. Live audio webcasts of ... 
Printer Friendly Version
11/10/16Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
PARSIPPANY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that senior leadership is scheduled to present an overview of the company at the following investor conferences in November: Jefferies 2016 London Healthcare Conference at 2:00 p.m. GMT (7:00 p.m. ET) in London on Thursday, November 17, 2016. 28th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET in New York on Tuesday, November 29, 2016. Live audio webcasts of ... 
Printer Friendly Version
11/02/16Pacira Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results
-- Total Net Revenues Up 10% Year-Over-Year -- -- EXPAREL® Net Product Sales Up 9% Year-Over-Year -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2016. “EXPAREL revenues continued to grow year-... 
Printer Friendly Version
10/20/16Pacira Pharmaceuticals Continues to Build Out Robust Commercial Leadership Team
Company Appoints Thomas Sluby as Vice President, Sales and Matthew Lehmann as Vice President, Marketing PARSIPPANY, N.J., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of two key individuals who will assume leadership roles within the company’s commercial organization. Thomas Sluby has been named Vice President, Sales and Matthew Lehmann has been appointed Vice President, Marketing – Emerging Therapies; both individuals will repor... 
Printer Friendly Version
10/17/16Pacira Pharmaceuticals Announces Timing for Third Quarter 2016 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2016 will be released before the market opens on Wednesday, November 2, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Wednesday, November 2, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (d... 
Printer Friendly Version
09/21/16Pacira Pharmaceuticals Announces Official Launch of EXPAREL to the Oral Surgeon Community to Treat Pain Following Oral and Maxillofacial Procedures
New research presented at AAOMS 2016 shows EXPAREL is safe and effective for pain relief following removal of wisdom teeth PARSIPPANY, N.J., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced new data regarding the benefit of EXPAREL® (bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking the official launch of the product to the oral surgeon community. EXPAREL is a local analgesic that pro... 
Printer Friendly Version
09/01/16Pacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
PARSIPPANY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 11:05 a.m. ET on Monday, September 12, 2016, in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” sec... 
Printer Friendly Version
>> Access Older Press Releases
Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com